Teva’s Patent for Copaxone Upheld by New York Federal Court

U.S. District Judge Barbara Jones in Manhattan today ruled that drug applications by Sandoz and Mylan for generic versions of TEVA’s patented drug, Copaxone, a pharmaceutical treatment for multiple sclerosis medicine “infringe all of the asserted claims.”

Teva sued Basel, Switzerland-based Novartis and Cambridge, Massachusetts-based Momenta, saying that copies of Copaxone would infringe four patents that expire in 2014.

The Federal Judge has now ruled that the infringed claims are valid and enforceable.

Momenta, a further company attempting to bring a generic version of the product to market was not mentioned in the ruling.

The case is Teva Pharmaceuticals USA Inc. v. Sandoz Inc., 08-cv-07611, U.S. District Court, Southern District of New York (Manhattan).